Crohn's disease
Gastroenterology · 2007–2026
52decisions
11medicines
35carried consumer input
233individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| upadacitinib Treatment of complex refractory fistulising Crohn's disease in patients with externally draining enterocutaneous or rectovaginal fistula. | Mar 2026 | Recommended with restriction | input received |
| adalimumab Immune-mediated inflammatory diseases (IMIDs) in paediatric patients, including juvenile idiopathic arthritis, Crohn disease, ulcerative colitis, psoriasis,… | Jul 2025 | Deferred | 6 individuals |
| guselkumab Treatment of adults with severe Crohn's disease who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a… | Jul 2025 | Recommended with restriction | 1 individuals Colitis Australia |
| infliximab Rheumatoid arthritis, psoriatic arthritis, Crohn's disease (adults and children 6-17 years), refractory Crohn's disease, ankylosing spondylitis, psoriasis, and… | Jul 2025 | Recommended with restriction | input received Colitis Australia |
| infliximab Biosimilar to reference infliximab for multiple indications: rheumatoid arthritis, psoriatic arthritis, Crohn's disease (adults and children/adolescents 6–17… | Mar 2025 | Recommended with restriction | input received Australasian Society of Clinical Immunology and Allergy |
| infliximab Continuing treatment and balance of supply of infliximab 120 mg subcutaneous injection for ankylosing spondylitis, severe Crohn disease, severe chronic plaque… | Mar 2025 | Recommended with restriction | input received Australasian Society of Clinical Immunology and Allergy |
| ustekinumab Biosimilar to Stelara for severe chronic plaque psoriasis, severe psoriatic arthritis, severe Crohn disease, complex refractory fistulising Crohn disease, and… | Mar 2025 | Recommended | input received |
| vedolizumab Dose escalation from 8-weekly to 4-weekly maintenance treatment in adults with moderate to severe ulcerative colitis or severe Crohn disease who have… | Nov 2025 | Recommended with restriction | input received Colitis Australia |
| adalimumab Biosimilar adalimumab for multiple indications including severe Crohn disease, moderate to severe ulcerative colitis, severe active juvenile idiopathic… | Jul 2024 | Recommended with restriction | none received |
| adalimumab Complex refractory fistulising Crohn disease, severe Crohn disease, moderate to severe ulcerative colitis, moderate to severe hidradenitis suppurativa, and… | Mar 2024 | Recommended with restriction | input received Colitis Australia |
| budesonide Mild to moderately active Crohn disease affecting the ileum and/or the ascending colon. | Mar 2024 | Recommended | input received Colitis Australia |
| ustekinumab Treatment of paediatric severe chronic plaque psoriasis, severe Crohn disease, moderate to severe ulcerative colitis, complex refractory fistulising Crohn… | Mar 2024 | Recommended with restriction | input received Colitis Australia |
| vedolizumab Treatment of severe Crohn disease for patients who have not responded to therapy after the existing three dose induction therapy (additional dose at week 10). | Mar 2024 | Recommended with restriction | input received Colitis Australia |
| ustekinumab Severe chronic plaque psoriasis (adult and paediatric), severe psoriatic arthritis, severe Crohn disease, complex refractory fistulising Crohn disease, and… | Nov 2024 | Recommended with restriction | input received Colitis Australia |
| adalimumab Biosimilar adalimumab for multiple indications including severe Crohn disease, moderate to severe ulcerative colitis, severe active juvenile idiopathic… | Jul 2023 | Recommended with restriction | input received |
| upadacitinib Treatment of severe Crohn disease in adults who have failed to achieve an adequate response, or are contraindicated, to prior systemic therapy. | Jul 2023 | Recommended with restriction | input received Colitis Australia |
| ustekinumab Treatment of complex refractory fistulising Crohn disease in adult patients. | Jul 2023 | Recommended with restriction | input received Colitis Australia |
| risankizumab Treatment of severe Crohn's disease in adults who have failed to achieve an adequate response, or are contraindicated, to prior systemic therapy. | Jul 2022 | Deferred | input received Colitis Australia |
| ustekinumab Treatment of patients with Crohn disease and severe chronic plaque psoriasis requiring a 90 mg dose of ustekinumab, in a 90 mg pre-filled syringe formulation. | Jul 2022 | Recommended | none received |
| infliximab Treatment of ankylosing spondylitis (AS), severe chronic plaque psoriasis (CPP), severe active psoriatic arthritis (PsA), and complex refractory fistulising… | Mar 2022 | Recommended | unclear |
| adalimumab; upadacitinib Change in restriction levels (Authority Required categories) for adalimumab across multiple indications (rheumatoid arthritis, ankylosing spondylitis,… | Nov 2022 | Noted | 1 individuals |
| adalimumab Biosimilar to Humira for multiple indications including severe Crohn disease, moderate to severe ulcerative colitis, severe active rheumatoid arthritis, severe… | Jul 2021 | Recommended with restriction | input received |
| adalimumab Biosimilar to adalimumab for multiple indications including severe Crohn disease, complex refractory fistulising Crohn disease, moderate to severe ulcerative… | Jul 2020 | Recommended with restriction | none received |
| adalimumab Biosimilar to Humira for multiple indications including severe Crohn disease, moderate to severe ulcerative colitis, severe active juvenile idiopathic… | Mar 2020 | Recommended | input received Colitis Australia |
| mesalazine Management of an acute episode of mild to moderate ulcerative proctitis (suppository); ulcerative colitis and Crohn disease (granules). | Mar 2020 | Recommended with restriction | 1 individuals Colitis Australia |
| Protein formula with carbohydrate, fat, vitamins, minerals and transforming growth factor beta-2 Dietary management of Crohn disease in the active or remission phases in adults and children over the age of 5 years. | Mar 2020 | Not recommended | input received Colitis Australia · Israel Medical Association |
| adalimumab Multiple indications including severe Crohn disease, moderate to severe ulcerative colitis, severe active juvenile idiopathic arthritis, complex refractory… | Nov 2020 | Recommended with restriction | input received Colitis Australia |
| infliximab Treatment of severe active rheumatoid arthritis, moderate to severe ulcerative colitis, and severe refractory Crohn's disease in adult patients via… | Nov 2020 | Recommended with restriction | input received Colitis Australia |
| vedolizumab Maintenance treatment for patients with moderate to severe ulcerative colitis (MSUC) and severe Crohn's disease (CD) who have responded to induction treatment… | Nov 2020 | Recommended with restriction | input received Colitis Australia |
| budesonide Treatment of mild to moderate Crohn's disease affecting the ileum and/or the ascending colon. | Mar 2019 | Recommended with restriction | 1 individuals |
| budesonide Induction of remission in mild to moderate Crohn's disease affecting the ileum and/or ascending colon. | Mar 2019 | Recommended with restriction | 2 individuals |
| infliximab Increase in maximum quantity from 4 to 5 vials for subsequent continuing treatment of severe Crohn disease, complex refractory fistulising Crohn disease,… | Mar 2019 | Recommended with restriction | 3 individuals |
| adalimumab Biosimilar of adalimumab for all indications for which Humira is currently PBS listed, including severe active rheumatoid arthritis, severe psoriatic… | Jul 2018 | Recommended with restriction | 1 individuals |
| adalimumab Multiple indications including severe Crohn's disease, moderate to severe ulcerative colitis, severe active juvenile idiopathic arthritis, fistulising Crohn's… | Jul 2018 | Recommended with restriction | none received |
| budesonide Induction of remission in adult patients with mild to moderate Crohn's disease affecting the ileum and/or the ascending colon. | Jul 2018 | Recommended with restriction | input received Colitis Australia |
| adalimumab Treatment of severe Crohn's disease, moderate to severe ulcerative colitis, severe active juvenile idiopathic arthritis, fistulising Crohn's disease, moderate… | Jul 2018 | Recommended with restriction | none received |
| mesalazine Treatment of ulcerative colitis and Crohn disease in patients with documented hypersensitivity reaction to sulphonamides or intolerance to sulfasalazine. | Jul 2018 | Recommended | none received |
| ustekinumab Severe Crohn's disease in adult patients. Treatment of complex refractory fistulising Crohn's disease (not recommended). | Mar 2017 | Recommended with restriction | 41 individuals |
| budesonide Treatment of mild to moderate Crohn's disease affecting the ileum and/or the ascending colon. | Nov 2017 | Not recommended | 46 individuals Colitis Australia |
| infliximab Change to initial and continuing treatment restrictions for infliximab biosimilar, and application of biosimilar uptake measures for multiple indications… | Nov 2017 | Recommended with restriction | none received |
| infliximab Biosimilar infliximab for the same indications as Remicade: rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis, ulcerative colitis,… | Nov 2016 | Recommended with restriction | none received |
| infliximab Biosimilar to Remicade, indicated for rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis, ulcerative colitis, and Crohn's disease. | Jul 2015 | Recommended with restriction | 2 individuals |
| vedolizumab Treatment of moderate to severe Crohn's disease in adult patients who have had an inadequate response with, lost response to, or are intolerant to either… | Mar 2015 | Recommended with restriction | 98 individuals |
| adalimumab Treatment of severe refractory Crohn's disease in paediatric patients aged 6 to 17 years. | Nov 2014 | Recommended with restriction | 30 individuals |
| infliximab Complex fistulising Crohn disease with a draining enterocutaneous or rectovaginal fistula. Treatment includes induction therapy followed by maintenance therapy. | Mar 2010 | Recommended with restriction | no section in document |
| infliximab Complex fistulising Crohn disease with a draining enterocutaneous or rectovaginal fistula. | Mar 2010 | Recommended with restriction | no section in document |
| adalimumab Treatment of complex, refractory fistulising Crohn disease with a draining enterocutaneous or rectovaginal fistula. | Nov 2010 | Recommended with restriction | unclear |
| infliximab Treatment of refractory moderate to severe Crohn's disease in paediatric patients aged 6-17 years who have failed adequate trials of conventional therapy. | Jul 2007 | Recommended with restriction | no section in document |
| infliximab Treatment of refractory moderate to severe Crohn's disease in paediatric patients aged 6-17 years inclusive who have failed adequate trials of conventional… | Jul 2007 | Recommended with restriction | no section in document |
| infliximab Treatment of severe refractory Crohn's disease in patients who have failed conventional therapy. | Mar 2007 | Recommended with restriction | no section in document |
| adalimumab Treatment of patients with moderate to severe Crohn disease (CDAI > 300) or patients with an ileostomy or colectomy due to Crohn disease, where conventional… | Nov 2007 | Recommended with restriction | no section in document |
| adalimumab Treatment of patients with moderate to severe Crohn disease (CDAI > 300) or patients with an ileostomy or colectomy due to Crohn disease, in whom conventional… | Nov 2007 | Recommended with restriction | no section in document |
Who spoke
Colitis Australia · Australasian Society of Clinical Immunology and Allergy · Israel Medical Association
What the PBS pays
$1,819M in government benefit over 2024–25, across 3,739,475 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| ustekinumab | $538.3M |
| upadacitinib | $291.6M |
| adalimumab | $241.9M |
| vedolizumab | $182.8M |
| guselkumab | $167.6M |
| risankizumab | $108.9M |
| budesonide | $102.1M |
| Infliximab | $83.8M |
| infliximab | $83.8M |
| protein formula with carbohydrate, fat, vitamins, minerals and transforming growth factor beta-2 | $18M |
Appraised elsewhere
NICE, in England and Wales, has appraised 8 technologies for this condition, recommending 7 and declining 1. A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| guselkumabGuselkumab for previously treated moderately to severely active Crohn's disease | TA1095 | recommended | 2025-08 |
| mirikizumabMirikizumab for previously treated moderately to severely active Crohn's disease | TA1080 | recommended restricted | 2025-07 |
| upadacitinibUpadacitinib for previously treated moderately to severely active Crohn's disease | TA905 | recommended restricted | 2023-06 |
| risankizumabRisankizumab for previously treated moderately to severely active Crohn's disease | TA888 | recommended restricted | 2023-05 |
| darvadstrocelDarvadstrocel for treating complex perianal fistulas in Crohn's disease | TA556 | not recommended | 2019-01 |
| ustekinumabUstekinumab for moderately to severely active Crohn's disease after previous treatment | TA456 | recommended | 2017-07 |
| vedolizumabVedolizumab for treating moderately to severely active Crohn's disease after prior therapy | TA352 | recommended restricted | 2015-08 |
| infliximab and adalimumabInfliximab and adalimumab for the treatment of Crohn's disease | TA187 | recommended | 2010-05 |
Registered, not subsidised
Medicines on the ARTG for this condition with no PBAC record at all. Registration and subsidy are separate decisions: a medicine can be legally available in Australia and never have been put to the committee.
| Medicine | On the ARTG since | Registrations |
|---|---|---|
| sulfasalazinePYRALIN EN Sulfasalazine 500mg tablet | 1991 | 3 |
The ARTG export holds current registrations only, so the year is the earliest entry still on the register rather than a first-registration date. The condition here comes from the registered label, which is usually broader than the population a sponsor asks to have subsidised.
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 35 of 44 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.